Inventiva (NASDAQ:IVA) Sees Strong Trading Volume – Here’s What Happened

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) shares saw an uptick in trading volume on Monday . 894,351 shares were traded during mid-day trading, an increase of 99% from the previous session’s volume of 448,636 shares.The stock last traded at $5.6850 and had previously closed at $5.47.

Analyst Ratings Changes

IVA has been the subject of a number of research analyst reports. Barclays initiated coverage on shares of Inventiva in a report on Tuesday, January 27th. They issued an “overweight” rating and a $18.00 target price for the company. Truist Financial initiated coverage on Inventiva in a research report on Thursday, March 19th. They set a “buy” rating and a $13.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a research report on Thursday, January 22nd. UBS Group initiated coverage on shares of Inventiva in a research report on Wednesday, January 7th. They issued a “buy” rating and a $12.00 price objective on the stock. Finally, HC Wainwright set a $24.00 target price on shares of Inventiva and gave the company a “buy” rating in a report on Wednesday, January 28th. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $16.56.

Inventiva Stock Performance

The business has a 50 day moving average of $6.17 and a 200 day moving average of $5.38.

Inventiva (NASDAQ:IVA) last released its earnings results on Saturday, February 14th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $0.01 million for the quarter. Research analysts expect that Inventiva S.A. Sponsored ADR will post -2.08 EPS for the current year.

Institutional Trading of Inventiva

A number of hedge funds have recently bought and sold shares of IVA. Quadrature Capital Ltd acquired a new stake in shares of Inventiva during the fourth quarter worth $311,000. NewEdge Advisors LLC acquired a new position in Inventiva in the third quarter valued at $116,000. Cerity Partners LLC purchased a new position in Inventiva during the fourth quarter worth about $93,000. XTX Topco Ltd acquired a new stake in Inventiva in the 4th quarter worth about $84,000. Finally, Virtu Financial LLC purchased a new stake in Inventiva in the 4th quarter valued at about $60,000. Institutional investors and hedge funds own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva (NASDAQ: IVA) is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company’s core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva’s scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.

The company’s lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.